Canine chronic bronchitis (CCB) is an inflammatory airway disease characterized by cough lasting ≥2 months in the absence of other primary cardiorespiratory disease. The action of substance P and its neurokinin 1-receptor (NK1-R) is involved in airway inflammation and the cough reflex. Cough suppressants alone are inadequate to treat CCB because they decrease clinical signs without treating underlying inflammation; this can lead to irreversible pulmonary changes and progression of disease. Maropitant, a potent NK 1-R antagonist, has been anecdotally used to treat canine CCB.

The authors concluded that maropitant is not suitable as a sole treatment for CCB because of its lack of benefit for airway inflammation. Future placebo-controlled studies are warranted to determine the efficacy of maropitant as a cough suppressant for dogs with CCB.


Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.
Up Next